Strata Skin Sciences

SSKN

Market cap $1.12M

HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and confirms that trading of the Company's common stock has been suspended from trading on The Nasdaq Capital Market (“Nasdaq”) at the opening of business on February 19, 2026. The Company also expects to file a Form 15 with the SEC on or about March 2, 2026, to commence the process of terminating the registration of its common stock under Section 12(g) of the Exchange Act and to suspend the Company's reporting obligations under Sections 13(a) and 15(d) of the Exchange Act, which we refer to as “going dark”.

STRATA Skin Sciences plunges 8% despite new meta-analysis backing its 308 nm excimer laser with up to 85% PASI improvement in plaque psoriasis.

HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatment offerings.

Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions

LAGUNA HILLS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Laseroptek America Corp. (“Laseroptek America” or “LOA”) today announced that it has filed counterclaims and third-party claims against Strata Skin Sciences, Inc. (“Strata”) and its Chief Executive Officer, Dolev Rafaeli, in the lawsuit brought by Strata.

HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting growing adoption of this innovative acne treatment modality by dermatologists in the region.

STRATA Skin Sciences, Inc. ( SSKN ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Dolev Rafaeli - President, CEO & Vice-Chairman John Gillings - Principal Financial Officer & Chief Accounting Officer Conference Call Participants Jules Abraham - CorProminence, LLC Destiny Buch - Ladenburg Thalmann & Co. Inc., Research Division Jeremy Pearlman - Maxim Group LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences, Inc. Third Quarter 2025 Financial Results and Corporate Update Conference Call.

Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion

HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close.

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTRAC capability to address the condition